Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes
|
|
- Wilfred Higgins
- 5 years ago
- Views:
Transcription
1 Neuro-Oncology Neuro-Oncology 17(6), , 2015 doi: /neuonc/nou347 Advance Access date 27 December 2014 Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes Arjun Sahgal, Michael W. Chan, Eshetu G. Atenafu, Laurence Masson-Cote, Gaurav Bahl, Eugene Yu, Barbara-Ann Millar, Caroline Chung, Charles Catton, Brian O Sullivan, Jonathan C. Irish, Ralph Gilbert, Gelareh Zadeh, Michael Cusimano, Fred Gentili, and Normand J. Laperriere Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada (A.S.); Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada (A.S., L.M.-C., G.B., B.-A.M., C.C., C.C., B.O., N.J.L.); Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada (M.W.C.); Department of Biostatistics, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada (E.G.A); Department of Radiology, University Health Network, University of Toronto, Toronto, Ontario, Canada (E.Y.); Department of Otolaryngology Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada (J.C.I., R.G.); Division of Neurosurgery, Department of Surgery, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada (G.Z., F.G.); Department of Neurosurgery, St Michaels Hospital, University of Toronto, Toronto, Ontario, Canada (M.C.) Corresponding Author: Arjun Sahgal, MD, Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada (arjun.sahgal@sunnybrook.ca). Background. We report our preliminary outcomes following high-dose image-guided intensity modulated radiotherapy (IG-IMRT) for skull base chordoma and chondrosarcoma. Methods. Forty-two consecutive IG-IMRT patients, with either skull base chordoma (n ¼ 24) or chondrosarcoma (n ¼ 18) treated between August 2001 and December 2012 were reviewed. The median follow-up was 36 months (range, 3 90 mo) in the chordoma cohort, and 67 months (range, ) in the chondrosarcoma cohort. Initial surgery included biopsy (7% of patients), subtotal resection (57% of patients), and gross total resection (36% of patients). The median IG-IMRT total doses in the chondrosarcoma and chordoma cohorts were 70 Gy and 76 Gy, respectively, delivered with 2 Gy/fraction. Results. For the chordoma and chondrosarcoma cohorts, the 5-year overall survival and local control rates were 85.6% and 65.3%, and 87.8% and 88.1%, respectively. In total, 10 patients progressed locally: 8 were chordoma patients and 2 chondrosarcoma patients. Both chondrosarcoma failures were in higher-grade tumors (grades 2 and 3). None of the 8 patients with grade 1 chondrosarcoma failed, with a median follow-up of 77 months (range, ). There were 8 radiation-induced late effects the most significant was a radiation-induced secondary malignancy occurring 6.7 years following IG-IMRT. Gross total resection and age were predictors of local control in the chordoma and chondrosarcoma patients, respectively. Conclusions. We report favorable survival, local control and adverse event rates following high dose IG-IMRT. Further follow-up is needed to confirm long-term efficacy. Keywords: chondrosarcoma, chordoma, image-guided intensity modulated radiotherapy, photon radiation. Skull base chondrosarcoma arises from endochondral bone in the cerebellopontine angle, paranasal sinuses, parasellar area, and clivus. Chordoma arises from ectopic notochord remnants, and approximately a third are within the skull base. 1 Although both tumors are generally indolent and considered low grade, they are locally destructive, invasive, and fatal if not properly managed. The focus of this report is on skull base chordoma and chondrosarcoma. Surgery is the first line of therapy, with the aim to maximally debulk gross tumor. 2 Optimally, a gross total resection (GTR) is performed; however, in the skull base, the location is such that critical structures are inevitably intricate to the tumor position, making an en bloc, or GTR, often not possible. In fact, residual tumor is often left intentionally as a Received 22 October 2014; accepted 21 November 2014 # The Author(s) Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please journals.permissions@oup.com. 889
2 consequence of preserving function depending on where the tumor is, and subtotal resection (STR) is often the postoperative result. Regardless of the extent of resection, local failure rates with surgery alone can be significant, and adjuvant radiation is considered a standard therapeutic option postoperatively. Within the radiation oncology department at the University of Toronto, our practice has been to offer all patients with skull base chordoma and chondrosarcoma adjuvant radiotherapy. As the therapeutic intent of radiation is to reduce the risk of local recurrence and increase survival, high doses of radiation are required, as these tumors are considered relatively radioresistant. 3,4 However, similar to surgery, the inherent proximity to several organs at risk (OAR) presents a major challenge with respect to covering the target volume with the prescribed high dose. While we often make sacrifices to respect the OAR radiation tolerance, we also frequently allow greater dose exposure than traditionally deemed acceptable. Hence, radiation is also a high-risk procedure and requires treatment in centers with experienced practitioners. The historical inability of previous linear accelerator technology to shape and modulate the radiation beam is why largely ineffective low doses of radiation (ranging from 40 to 54 Gy in Gy/d fraction sizes) were delivered, and yielded suboptimal local control (LC) rates. 5 As a result, some even questioned the role of radiation altogether, in particular for chordoma. As proton therapy became available for medical use, chordoma and chondrosarcoma were amongst the first to be considered for this technology. The advantage for protons compared with conventional radiation lies in the dose profile, which allows a predictable edge in the dose fall-off with minimal exit dose. 6 As a result, protons allow for higher doses to be deposited adjacent to the OAR, hence protons have become a standard of care. Over the last decade, photon-based linear accelerator technology has undergone a transformation. Multileaf collimators (MLCs) allow for intensity modulated radiotherapy (IMRT), while on-board image-guidance (IG) systems permit near-realtime tracking during delivery, and robotic technology has been incorporated to ensure millimeter precision in dose delivery. Ultimately, this translates into the ability to create sophisticated dose distributions with steep dose gradients that differentially dose the OAR and target, a reduction in the planning target volume margin, and excellent precision in the delivery, such that several centers have adopted IG-IMRT for skull base chordoma and chondrosarcoma, delivering equivalent doses to those typical of proton therapy We report initial outcomes using high-dose IG-IMRT. Materials and Methods A total of 42 consecutive patients with skull base chordoma or chondrosarcoma operated upon and treated with IG-IMRT between August 2001 and December 2012 were identified from the Princess Margaret Hospital tumor registry and retrospectively reviewed. Institutional research ethics board approval was obtained. All patients had their pathology reviewed at the University of Toronto. No patient received concurrent or adjuvant chemotherapy. Forty of 42 patients were treated with postoperative adjuvant radiotherapy within 6 months of surgery, and 2 of 42 were treated within 10 months of surgery. With respect to the latter 2 cases, the delay in starting radiation was to maximize postoperative healing, as our practice is to radiate typically within 6 months of the initial surgery. Thirteen patients were immobilized using a relocatable stereotactic frame, treated using stereotactic fixed field IMRT with an MLC-based system, and planned using Radionics. In these patients, cone-beam CT was not required, and the Radionics stereotactic localization approach applied. The remaining patients were immobilized using a thermoplastic mask, treated using MLC-based fixed field IMRT, and planned using Pinnacle (Philips Healthcare). Cone-beam CT was used for daily image guidance. Treatment planning consisted of thin-slice CT simulation (typically, mm) and fusion of T1 post-gadolinium and T2 axial and/or T2 fluid attenuation inversion recovery volumetric MR sequences. The gross tumor volume (GTV) was defined as all gross disease visible on imaging and the postoperative surgical bed. The clinical target volume (CTV) consisted of a 0.5-cm margin beyond the GTV and, where applicable, a more generous margin to include those anatomic areas at risk of microscopic extension (for example, if the cavernous sinus is invaded, then the relevant portion of the cavernous sinus is taken as CTV). The planning target volume (PTV) typically consisted of a 0.2- to 0.3-cm margin beyond the CTV depending on the immobilization technique. With respect to the PTV, the aim was to achieve 90% 95% coverage with the prescribed dose (our practice is to prescribe to the International Commission on Radiation Units and Measurements point). In circumstances where the PTV overlapped with dose limiting OAR, then compromises in target coverage were allowed such that coverage of the PTV by 85% 90% of the prescribed dose was permitted. Of note, our typical practice is to plan on one PTV, and not designated multiple CTVs and PTVs with different dose levels (for example, separate high-dose and low-dose volumes). A representative dose distribution for a chordoma case treated with 78 Gy in 39 fractions is shown in Fig. 1. The primary endpoints of this study were LC and overall survival (OS). LC was defined as imaging-based disease progression using the postoperative radiation treatment planning imaging as reference, and a dedicated neuroradiologist reviewed each case. Radiation-related injuries were graded according to the National Cancer Institute s Common Terminology Criteria for Adverse Events v4.0. Statistical Analysis Descriptive statistics were used to assess selected patient demographics, disease characteristics, and treatment details. Expressed as count and proportions were categorical variables such as gender, primary diagnosis, Eastern Cooperative Oncology Group performance status, clinical signs and symptoms at presentation (presence of pain, cranial nerve palsy, neurologic deficits, and hydrocephalus), location of the tumor within the skull base, and extent of surgery, whereas continuous variables such as age, maximum diameter of the tumor at presentation, total dose, dose per fraction, and follow-up were expressed as mean+sd or median and range. The outcome variable of interest was the time to local failure and OS. The time-to-event data 890
3 Fig. 1. (A) Axial T1-weighted MRI of a skull base chordoma involving the clivus and cavernous sinus that was subtotally resected. The patient received 78 Gy in 39 fractions with IG-IMRT. (B) Axial treatment planning CT slice with the dose distribution and representative isodose lines and (C) sagittal treatment planning CT slice with the dose distribution and representative isodose lines. were calculated in months from the date of radiation to the date of the event (date of local failure and death data for OS), or last follow-up if the event had not yet occurred. OS survival probabilities were calculated using the Kaplan Meier product-limit method. LC was based on the competing risk model with death as the competing risk. The log-rank test was used as a univariate analysis to compare OS probability with a potential predictor of interest, and Fine and Gray s method was used to compare LC. A multivariate Cox proportional hazards regression model was used to determine the joint effect of potential factors for OS, and Fine and Gray s model was used to determine the joint effect of factors for LC that were found to be potential on univariate analysis. All P-values were 2-sided. Results were considered significant if P,.05. Statistical analyses were performed using SAS v9.3 and the user s guide and the open source statistical software R v3.0. Results The baseline characteristics separated according to the chordoma and chondrosarcoma cohorts are summarized in Table 1. Of the 18 cases of chondrosarcoma, 8 were grade 1; 9 were grade 2; and 1 was grade 3. The median total dose was 76 Gy (range, Gy) and 70 Gy (range, Gy) for the chordoma and chondrosarcoma groups, respectively. The dose per fraction was uniformly 2.0 Gy per day. The median follow-up in the chordoma cohort was 36 months (range, 3 90), and in the chondrosarcoma cohort 67 months (range, ). The total dose exposures to the critical OAR are summarized in Table 2. In total, 10 patients exhibited local disease progression. Eight of the 10 were in the chordoma cohort (n ¼ 24) and 2/10 in the chondrosarcoma cohort (n ¼ 18) (P ¼.077). With respect to the chondrosarcoma failures, both were in highergrade disease (grades 2 and 3). The grade 3 chondrosarcoma patient also developed systemic metastases 13 months following radiation, in addition to a local recurrence. None of the 8 grade 1 chondrosarcoma patients experienced a local failure, with a median follow-up of 77 months (range, ). Four patients died in the chordoma group, and 3 of these patients died as a consequence of local disease progression. Three patients died in the chondrosarcoma group, with 2 cases as a consequence of local disease progression. Table 3 summarizes the local failure characteristics in detail for each of the 10 cases. To summarize the 8 chordoma failures, 8/8 patients (100%) underwent STR, and 1 had been treated with,66 Gy. Of the 2 chondrosarcoma failures, one was grade 2 and the other grade 3. Both patients had undergone an initial STR and were treated with a total dose of 70 Gy. Of the chordoma and chondrosarcoma patients who progressed, the median time to progression was 1.5 and 1.3 years, respectively. The Kaplan Meier OS curves are shown in Fig. 2. The 3- and 5-year OS rates were 100% and 85.6% and 87.8% and 84.1% for the chordoma and chondrosarcoma cohorts, respectively. The 5-year cumulative incidences of local failure were 34.7% and 11.9% for the chordoma and chondrosarcoma cohorts, respectively (Fig. 3). Specific to the chordoma cohort, a trend was observed for age as a continuous variable with respect to OS such that the rate of dying increased with increasing age (P ¼.05). With respect to LC, multivariable analysis confirmed GTR as a significantpredictorcomparedwithstrandbiopsy(p,.0001). With respect to dose, we did not find any significance with total dose as a continuous variable. For chondrosarcoma, we could not identify any significant prognostic factors for OS, although age was a predictor for LC associated with an increased risk of local progression (hazard ratio ¼ [ ], P ¼.0007). There were 6 patients with 8 radiation-induced late injuries. The median and mean times to injury from the start of radiation were 2.2 years and 3.2 years, respectively. Three of 8 were cases of radiation-induced hearing loss (2 cases grade 2, one case grade 3), 1 was radiation-induced hypothyroidism (grade 2), 1 was radiation-induced hypopituitarism (grade 3), 1 was radiation-induced vestibular nerve injury (grade 2), 1 was a cranial nerve IV injury resulting in diplopia (grade 2), and 1 was a radiation-induced secondary malignancy that resulted in death (grade 5). This last was consistent with the development of a radiation-induced malignant glioma based on MRI findings; Neuro-Oncology 891
4 Table 1. Descriptive statistics for the chordoma and chondrosarcoma patients Variable Chordoma (n ¼ 24) Chondrosarcoma (n ¼ 18) Sex, F 8 (33.3%) 8 (44.4%) Site of disease Petroclival 17 (70.8%) 12 (66.7%) Parasellar 2 (8.3%) 1 (5.6%) Cervical spine/foramen magnum 2 (8.33%) 0 (0%) Cerebellopontine angle 1 (4.2%) 0 (0%) Posterior fossa 1 (4.2%) 0 (0%) Sellar 1 (4.2%) 0 (0%) Cavernous sinus 0 (0%) 3 (16.7%) Other 0 (0%) 2 (11.1%) Cranial nerve palsy present 10 (41.7%) 13 (72.2%) Neurologic deficit present 4 (16.7%) 3 (16.7%) Surgical outcome GTR 8 (33.3%) 7 (38.9%) STR 15 (62.5%) 9 (50.0%) Biopsy only 1 (4.2%) 2 (11.1%) Median age, y (range) 46 (21 76) 32 (21 69) Median total dose (range)/median dose per fraction Gy ( )/2.0 Gy Gy ( )/2.0 Gy Median range tumor diameter, cm (range) 3.50 ( ) 3.10 ( ) Median GTV, cc (range) 14.5 ( ) 24.6 ( ) Median time from surgery to radiation, d (range) 86.5 (11 229) 69 (27 298) Median follow-up, mo (range) 36.1 ( ) 66.5 ( ) Table 2. Median (range) total dose for selected critical organs at risk Variable Chordoma (n ¼ 24) Chondrosarcoma (n ¼ 18) Optic chiasm max dose Gy ( ) Gy ( ) Optic chiasm mean dose Gy ( ) Gy ( ) Right optic nerve max dose Gy ( ) Gy ( ) Right optic nerve mean dose Gy ( ) Gy ( ) Left optic nerve max dose Gy ( ) Gy ( ) Left optic nerve mean dose Gy ( ) Gy ( ) Brainstem max dose Gy ( ) Gy ( ) Brainstem mean dose Gy ( ) Gy ( ) location within the prior radiation field (developed within the brainstem), prolonged time to diagnosis at 6.7 years following the initial chordoma radiation, and the patient had no evidence of primary tumor recurrence. Mature follow-up is required to assess the long-term consequences of this treatment. Discussion We report favorable preliminary rates of LC for both chondrosarcoma and chordoma following high-dose photon linear accelerator IG-IMRT. We observed crude LC in 67% of chordoma patients and 88% of chondrosarcoma patients. The 5-year actuarial LC and OS rates were 65.3% and 88.1% and 85.6% and 84.1% in the chordoma and chondrosarcoma cohorts, respectively. With respect to grade 1 chondrosarcoma, no failures were observed, with a median follow-up of 77 months (range, ). These data are consistent with expected outcomes following proton therapy as summarized in a recent review by Combs and colleagues. 11 There has been controversy over the years as to the importance of high-dose versus low-dose photon-based radiation and which radiation technology is best suited for these patients. Prior to IG-IMRT, rates of LC with conventional photon radiation delivering total doses in the range of 40 to 54 Gy were suboptimal. Local control rates, especially after incomplete resection, were well below 50%, and the utility of radiation was questioned and even considered to be a palliative treatment. 5,12 14 The inability to dose escalate without IG-IMRT led to the referral of these patients to highly specialized particle therapy radiation centers. The advantage of particle therapy lies in the predictable dose deposition at a given depth, essentially allowing for maximal dosing at the tumor/oar interface and consequent dose escalation within the tumor. 6 Therefore, 892
5 Table 3. Summary of clinical factors in those patients who subsequently failed locally Variable Chordoma (n ¼ 8) Chondrosarcoma* (n ¼ 2) Sex, F 3 (37.5%) 1 (50%) Site of disease Petroclival 4 (50%) 2 (100%) Parasellar 2 (25%) 0 (0%) Cervical spine/foramen magnum 1 (12.5%) 0 (0%) Sellar 1 (12.5%) 0 (0%) Initial surgical outcome STR 8 (100%) 2 (100%) Median age, y (range) 63 (29 76) 55 (49 61) Median total dose (range)/dose per fraction Gy ( )/2.0 Gy Gy ( )/2.0 Gy Median maximum tumor diameter, cm (range) 2.90 ( ) 3.90 ( ) Median tumor volume, cc (range) ( ) ( ) Median time from surgery to radiation, d (range) 73 (11 205) 30.5 (27 34) Median time from start of radiation to failure, y (range) 1.5 ( ) 1.3 ( ) *Note that the chondrosarcoma failures were patients with grade 2 and 3 disease; no patient with grade 1 chondrosarcoma relapsed. Fig. 2. Kaplan Meier survival curve illustrating OS by tumor type. higher doses were able to be delivered than otherwise possible with conventional radiation. The outcomes were favorable compared with low-dose conventional radiation; however, with IG-IMRT the landscape has changed and similar doses to those typical of proton therapy are now being delivered with photon therapy as per our series. 4 The advantage of IMRT is modulation of the beam to create exquisitely shaped radiation dose distributions with steep dose fall-offatthetumor/oarinterface.imageguidanceallows millimetric precision in delivery, allowing for the PTV margins to be kept to a minimum. Although the integral dose will undoubtedly be greater with photons versus protons, the clinical significance relates to the potential for adverse effects as opposed to tumor control. Both the tumor control and adverse late-effects results presented in this series are consistent with those with proton-based radiation for both chordoma and chondrosarcoma and the few series reported with IG-IMRT to date. 4,7 10,15,18 A recent series evaluating carbon ion therapy for chordoma also report reasonably consistent results with Fig. 3. Cumulative incidence curve of tumor recurrence according to tumor type. our data. 19 Therefore, we conclude both efficacy and safety with modern linear accelerator based IG-IMRT technology. We acknowledge that comparability between series is difficult due to the heterogeneity of the disease characteristics at the time of treatment, complexity of the radiation dose distribution, and at this time the lack of molecular subclassifications to clarify biological aggressiveness. With respect to our chondrosarcoma patients (n ¼ 18), our results were consistent with the high-dose proton and photon literature, with only 2 failures observed. 4,7 10,15 17 Both failures occurred in the patients with higher-grade disease, also known to be associated with failure. One case was grade 2 and the other grade 3 chondrosarcoma, and both were treated with 70 Gy in 35 fractions. This result may suggest that patients with higher-grade chondrosarcoma should be dose escalated; however, the limited sample size in this study must be considered before any firm recommendations can be made. Importantly, none of the grade 1 tumors relapsed. Neuro-Oncology 893
6 In the chordoma cohort (n ¼ 24), the median total dose was 76 Gy and only one patient was treated with,66 Gy. We did not observe a dose response relationship within the narrow dose range employed. Surgery for chordoma was predictive of better outcomes when a GTR was performed compared with STR and biopsy alone. This likely reflects the therapeutic benefit of resecting as much tumor as possible given that chordoma is considered radioresistant, and less residual disease to control with radiation likely increases the chance for radiation to achieve long-term control. With respect to the toxicities observed, these are in keeping with most major series. 4,7 10,15 18 The one case of radiationinduced malignancy highlights the discussion that must take place when consenting patients for radiation; as this is a serious late effect, albeit low risk, of radiation in long-term survivors. Our preliminary data support our practice of treating with linear accelerator based photon IG-IMRT, and we now routinely treat with 70 Gy in 35 fractions for chondrosarcomas and 78 Gy in 39 fractions for chordomas. We acknowledge that analogous IG-IMRT technology is emerging for protons, with the advent of intensity-modulated proton therapy and in-room cone-beam CT. Ultimately, future evaluation will determine if these advances in proton technology can yield better results with respect to LC. Funding There are no funding sources to disclose. Conflict of interest statement. Dr Arjun Sahgal has received honoraria for previous educational seminars and research funding from Elekta AB. There are no other conflicts of interest to disclose. References 1. Walcott BP, Nahed BV, Mohyeldin A, et al. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13(2):e69 e Colli BO, Al-Mefty O. Chordomas of the skull base: follow-up review and prognostic factors. Neurosurg Focus. 2001;10(3):E1. 3. Fagundes MA, Hug EB, Liebsch NJ, et al. Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse. Int J Radiat Oncol Biol Phys. 1995;33(3): Koga T, Shin M, Saito N. Treatment with high marginal dose is mandatory to achieve long-term control of skull base chordomas and chondrosarcomas by means of stereotactic radiosurgery. J Neurooncol. 2010;98(2): Catton C, O Sullivan B, Bell R, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol. 1996;41(1): Amichetti M, Amelio D, Minniti G. Radiosurgery with photons or protons for benign and malignant tumours of the skull base: a review. Radiat Oncol. 2012;7: Kano H, Iqbal FO, Sheehan J, et al. Stereotactic radiosurgery for chordoma: a report from the North American Gamma Knife Consortium. Neurosurgery. 2011;68(2): Martin JJ, Niranjan A, Kondziolka D, et al. Radiosurgery for chordomas and chondrosarcomas of the skull base. J Neurosurg. 2007;107(4): Hasegawa T, Ishii D, Kida Y, et al. Gamma knife surgery for skull base chordomas and chondrosarcomas. J Neurosurg. 2007; 107(4): Ito E, Saito K, Okada T, et al. Long-term control of clival chordoma with initial aggressive surgical resection and gamma knife radiosurgery for recurrence. Acta Neurochir (Wien). 2010;152(1): 57 67; discussion Combs SE, Laperriere N, Brada M. Clinical controversies: proton radiation therapy for brain and skull base tumors. Semin Radiat Oncol. 2013;23(2): Cummings BJ, Hodson DI, Bush RS. Chordoma: the results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys. 1983;9(5): Zorlu F, Gurkaynak M, Yildiz F, et al. Conventional external radiotherapy in the management of clivus chordomas with overt residual disease. Neurol Sci. 2000;21(4): Fuller DB, Bloom JG. Radiotherapy for chordoma. Int J Radiat Oncol Biol Phys. 1988;15(2): Amichetti M, Cianchetti M, Amelio D, et al. Proton therapy in chordoma of the base of the skull: a systematic review. Neurosurg Rev. 2009;32(4): Amichetti M, Amelio D, Cianchetti M, et al. A systematic review of proton therapy in the treatment of chondrosarcoma of the skull base. Neurosurg Rev. 2010;33(2): Orecchia R, Vitolo V, Fiore MR, et al. Proton beam radiotherapy: report of the first ten patients treated at the Centro Nazionale di Adroterapia Oncologica (CNAO) for skull base and spine tumours. Radiol Med. 2014;119(4): Hauptman JS, Barkhoudarian G, Safaee M, et al. Challenges in linear accelerator radiotherapy for chordomas and chondrosarcomas of the skull base: focus on complications. Int J Radiat Oncol Biol Phys. 2012;83(2): Uhl M, Mattke M, Welzel T, et al. Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results. Cancer. 2014; 120(21):
Evaluation of Monaco treatment planning system for hypofractionated stereotactic volumetric arc radiotherapy of multiple brain metastases
Evaluation of Monaco treatment planning system for hypofractionated stereotactic volumetric arc radiotherapy of multiple brain metastases CASE STUDY Institution: Odette Cancer Centre Location: Sunnybrook
More informationSacral Chordoma: The Loma Linda University Radiation Medicine Experience. Kevin Yiee MD, MPH Resident Physician
Sacral Chordoma: The Loma Linda University Radiation Medicine Experience Kevin Yiee MD, MPH Resident Physician What is a chordoma? 1 st chordoma discovered in clivus by Virchow and Luschka 1856 Rare tumor
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MENINGIOMA CNS Site Group Meningioma Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION 3 2. PREVENTION
More informationFeasibility of Proton Beam Therapy for Chordoma and Chondrosarcoma of the Skull Base
ORIGINAL ARTICLE Feasibility of Proton Beam Therapy for Chordoma and Chondrosarcoma of the Skull Base Hiroshi Fuji, M.D., Ph.D., 1 Yoko Nakasu, M.D., Ph.D., 2 Yuji Ishida, M.D., Ph.D., 3 Satoshi Horiguchi,
More informationDisclosure SBRT. SBRT for Spinal Metastases 5/2/2010. No conflicts of interest. Overview
Stereotactic Body Radiotherapy (SBRT) for Recurrent Spine Tumors Arjun Sahgal M.D., F.R.C.P.C. Assistant Professor Princess Margaret Hospital Sunnybrook Health Sciences Center University of Toronto Department
More informationCarbon Ion Radiotherapy for Skull Base and Paracervical Chordomas
Carbon Ion Radiotherapy for Skull Base and Paracervical Chordomas Azusa Hasegawa, Jun-etsu Mizoe and Hirohiko Tsujii Research Center Hospital for Charged Particle Therapy National Institute of Radiological
More informationEvaluation of Three-dimensional Conformal Radiotherapy and Intensity Modulated Radiotherapy Techniques in High-Grade Gliomas
1 Carol Boyd Comprehensive Case Study July 11, 2013 Evaluation of Three-dimensional Conformal Radiotherapy and Intensity Modulated Radiotherapy Techniques in High-Grade Gliomas Abstract: Introduction:
More informationRadiotherapy and tumours in veterinary practice: part one
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Radiotherapy and tumours in veterinary practice: part one Author : Aleksandra Marcinowska, Jane Dobson Categories : Companion
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM EPENDYMOMA Last Revision Date July 2015 1 CNS Site Group Ependymoma Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2.
More informationChapters from Clinical Oncology
Chapters from Clinical Oncology Lecture notes University of Szeged Faculty of Medicine Department of Oncotherapy 2012. 1 RADIOTHERAPY Technical aspects Dr. Elemér Szil Introduction There are three possibilities
More informationRadiotherapy Considerations in Extremity Sarcoma
Radiotherapy Considerations in Extremity Sarcoma Peter Chung Department of Radiation Oncology Princess Margaret Hospital University of Toronto Role of RT in STS Local tumour eradication while allowing
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationProton-Radiotherapy for Tumors of the Skull Base: Indications, Advantages, Limitations
Proton-Radiotherapy for Tumors of the Skull Base: Indications, Advantages, Limitations Eugen B. Hug, MD Director, Center for Proton-Radiotherapy, Paul Scherrer Institut, Villigen and Chair of Proton-Radiotherapy.
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM GERM CELL TUMOURS CNS Site Group Germ Cell Tumours Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationA VMAT PLANNING SOLUTION FOR NECK CANCER PATIENTS USING THE PINNACLE 3 PLANNING SYSTEM *
Romanian Reports in Physics, Vol. 66, No. 2, P. 401 410, 2014 A VMAT PLANNING SOLUTION FOR NECK CANCER PATIENTS USING THE PINNACLE 3 PLANNING SYSTEM * M. D. SUDITU 1,2, D. ADAM 1,2, R. POPA 1,2, V. CIOCALTEI
More informationProton Therapy for tumors of the skull base - RESULTS. Eugen B. Hug, MD Medical Director, ProCure Proton Therapy Centers, NY
Proton Therapy for tumors of the skull base - RESULTS Eugen B. Hug, MD Medical Director, ProCure Proton Therapy Centers, NY Petroclival Chondrosarcoma: 68 72 Gy(RBE) at 1.8 or 2.0 Gy(RBE) GTV: 70.2 Gy(RBE)
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationParaganglioma of the Skull Base. Ross Zeitlin, MD Medical College of Wisconsin Milwaukee, WI
Paraganglioma of the Skull Base Ross Zeitlin, MD Medical College of Wisconsin Milwaukee, WI Case Presentation 63-year-old female presents with right-sided progressive conductive hearing loss for several
More informationAdvances in external beam radiotherapy
International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada
More informationA Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer
A Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer Tony Kin Ming Lam Radiation Planner Dr Patricia Lindsay, Radiation Physicist Dr John Kim, Radiation Oncologist Dr Kim Ann Ung,
More informationOtolaryngologist s Perspective of Stereotactic Radiosurgery
Otolaryngologist s Perspective of Stereotactic Radiosurgery Douglas E. Mattox, M.D. 25 th Alexandria International Combined ORL Conference April 18-20, 2007 Acoustic Neuroma Benign tumor of the schwann
More informationRadiation Technology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, JAPAN
Analysis of Visual Loss Due to Radiation- Induced Optic Neuropathy After Particle Therapy for Head and Neck and Skull Base Tumors Adjacent to Optic Nerves Y. Demizu 1, M. Murakami 1, D. Miyawaki 1, Y.
More informationOriginal Date: April 2016 Page 1 of 7 FOR CMS (MEDICARE) MEMBERS ONLY
National Imaging Associates, Inc. Clinical guidelines STEREOTACTIC RADIATION THERAPY: STEREO RADIOSURGERY (SRS) AND STEREOTACTIC BODY RADIATION THERAPY (SBRT) CPT4 Codes: Please refer to pages 5-6 LCD
More informationDosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer
Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer Tan Chek Wee 15 06 2016 National University Cancer Institute, Singapore Clinical Care Education Research
More informationEvaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer
1 Charles Poole April Case Study April 30, 2012 Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer Abstract: Introduction: This study
More informationProton Radiotherapy for Skull Base and Para-spinal Tumors
Proton Radiotherapy for Skull Base and Para-spinal Tumors Carmen Ares Primary tumors Tumors of the Skull Base - Chordomas, Chondrosarcomas Secondary infiltration or involvement by intracranial tumors -
More informationTreatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI)
Treatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI) Tagreed AL-ALAWI Medical Physicist King Abdullah Medical City- Jeddah Aim 1. Simplify and standardize
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM BRAIN METASTASES CNS Site Group Brain Metastases Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationOverview of MLC-based Linac Radiosurgery
SRT I: Comparison of SRT Techniques 1 Overview of MLC-based Linac Radiosurgery Grace Gwe-Ya Kim, Ph.D. DABR 2 MLC based Linac SRS Better conformity for irregular target Improved dose homogeneity inside
More informationInstitute of Oncology & Radiobiology. Havana, Cuba. INOR
Institute of Oncology & Radiobiology. Havana, Cuba. INOR 1 Transition from 2-D 2 D to 3-D 3 D conformal radiotherapy in high grade gliomas: : our experience in Cuba Chon. I, MD - Chi. D, MD - Alert.J,
More informationParticle Therapy for Tumors of the Skull Base. Eugen B. Hug, MD Medical Director, ProCure Proton Therapy Centers, NY
Particle Therapy for Tumors of the Skull Base Eugen B. Hug, MD Medical Director, ProCure Proton Therapy Centers, NY Particle Radiation Therapy for Tumors of the Skull Base Primary skull base tumors: Chordoma,
More informationIntensity modulated radiotherapy (IMRT) for treatment of post-operative high grade glioma in the right parietal region of brain
1 Carol Boyd March Case Study March 11, 2013 Intensity modulated radiotherapy (IMRT) for treatment of post-operative high grade glioma in the right parietal region of brain History of Present Illness:
More informationPage 1. Helical (Spiral) Tomotherapy. UW Helical Tomotherapy Unit. Helical (Spiral) Tomotherapy. MVCT of an Anesthetized Dog with a Sinus Tumor
Helical (Spiral) Tomotherapy Novel Clinical Applications of IMRT Linac Ring Gantry CT Detector X-Ray Fan Beam Binary Multileaf Collimator Binary MLC Leaves James S Welsh, MS, MD Department of Human Oncology
More informationClinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience
Clinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience Stephanie E. Combs, MD Department of Radiation Oncology University of Heidelberg, Germany Carbon ion RT at GSI Active beam delivery
More informationSarcoma and Radiation Therapy. Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington
Sarcoma and Radiation Therapy Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington Objective: Helping you make informed decisions Introduction Process Radiation
More informationDOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES
DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES Marco Krengli Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale A. Avogadro THE STANDARD OF CARE
More informationStereotactic Radiosurgery. Extracranial Stereotactic Radiosurgery. Linear accelerators. Basic technique. Indications of SRS
Stereotactic Radiosurgery Extracranial Stereotactic Radiosurgery Annette Quinn, MSN, RN Program Manager, University of Pittsburgh Medical Center Using stereotactic techniques, give a lethal dose of ionizing
More informationStereotactic radiosurgery and hypofractionated stereotactic radiotherapy for residual or recurrent cranial base and cervical chordomas
Neurosurg Focus 10 (3):Article 5, 2001, Click here to return to Table of Contents Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for residual or recurrent cranial base and cervical
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/36461 holds various files of this Leiden University dissertation Author: Wiggenraad, Ruud Title: Stereotactic radiotherapy of intracranial tumors : optimizing
More informationUpdate on Pediatric Brain Tumors
Update on Pediatric Brain Tumors David I. Sandberg, M.D. Director of Pediatric Neurosurgery & Associate Professor Dr. Marnie Rose Professorship in Pediatric Neurosurgery Pre-talk Questions for Audience
More informationProtocol of Radiotherapy for Head and Neck Cancer
106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high
More informationPEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING
PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING ANATOMY ANATOMY CONT ANATOMY CONT. ANATOMY CONT. EYE OF A CHILD Normal tissue tolerance doses (in conventional #) TD 5/5 TD 50/5 Endpoint Gy Gy Optic nerve
More informationA Patient s Guide to SRS
A Patient s Guide to SRS Stereotactic Radiosurgery 230 Nebraska St. Sioux City, IA 51101 NOTES 230 Nebraska St. Sioux City, IA 51101 Contents page Introduction 1 SRS and how it works 2 The technology involved
More informationWHOLE-BRAIN RADIOTHERAPY WITH SIMULTANEOUS INTEGRATED BOOST TO MULTIPLE BRAIN METASTASES USING VOLUMETRIC MODULATED ARC THERAPY
doi:10.1016/j.ijrobp.2009.03.029 Int. J. Radiation Oncology Biol. Phys., Vol. 75, No. 1, pp. 253 259, 2009 Copyright Ó 2009 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/09/$ see front
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationGamma knife radiosurgery for Koos grade 4 vestibular schwannomas
Gamma knife radiosurgery for Koos grade 4 vestibular schwannomas David Mathieu MD FRCSC, Christian Iorio-Morin MD PhD, Fahd Al Subaie MD MSc FRCSC Division of neurosurgery, Université de Sherbrooke, Centre
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationThe Physics of Oesophageal Cancer Radiotherapy
The Physics of Oesophageal Cancer Radiotherapy Dr. Philip Wai Radiotherapy Physics Royal Marsden Hospital 1 Contents Brief clinical introduction Imaging and Target definition Dose prescription & patient
More informationRadiation Therapy for Soft Tissue Sarcomas
Radiation Therapy for Soft Tissue Sarcomas Alexander R. Gottschalk, MD, PhD Assistant Professor, Radiation Oncology University of California, San Francisco 1/25/08 NCI: limb salvage vs. amputation 43 patients
More informationThis LCD recognizes these two distinct treatment approaches and is specific to treatment delivery:
National Imaging Associates, Inc. Clinical guidelines STEREOTACTIC RADIOSURGERY (SRS) AND STEREOTACTIC BODY RADIATION THERAPY (SBRT) CPT4 Codes: 77371, 77372, 77373 LCD ID Number: L33410 J-N FL Responsible
More informationEffectiveness and Safety of Spot Scanning Proton Radiation Therapy for Skull Base Tumors: First Long Term Report of the PSI Experience
Effectiveness and Safety of Spot Scanning Proton Radiation Therapy for Skull Base Tumors: First Long Term Report of the PSI Experience Carmen Ares, Antony J Lomax, Eugen B Hug, Alessandra Bolsi, Beate
More informationStereotactic radiotherapy
Stereotactic radiotherapy Influence of patient positioning and fixation on treatment planning - clinical results Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH
More informationKEY WORDS chondrosarcoma; Gamma Knife; stereotactic radiosurgery; skull base tumor; oncology
clinical article J Neurosurg 123:1268 1275, 2015 Skull base chondrosarcoma radiosurgery: report of the North American Gamma Knife Consortium Hideyuki Kano, MD, PhD, 1 Jason Sheehan, MD, PhD, 2 Penny K.
More information8/3/2017. Spine SBRT: A Clinician's Update On Techniques and Outcomes. Disclosures. Outline
Spine SBRT: A Clinician's Update On Techniques and Outcomes Chia-Lin (Eric) Tseng, MD FRCPC Radiation Oncologist Sunnybrook Health Sciences Centre University of Toronto August 3, 2017 Disclosures I have
More informationRadiotherapy in the management of optic pathway gliomas
Turkish Journal of Cancer Vol.30/ No.1/2000 Radiotherapy in the management of optic pathway gliomas FARUK ZORLU, FERAH YILDIZ, MURAT GÜRKAYNAK, FADIL AKYOL, İ. LALE ATAHAN Department of Radiation Oncology,
More informationEfficient SIB-IMRT planning of head & neck patients with Pinnacle 3 -DMPO
Investigations and research Efficient SIB-IMRT planning of head & neck patients with Pinnacle 3 -DMPO M. Kunze-Busch P. van Kollenburg Department of Radiation Oncology, Radboud University Nijmegen Medical
More informationDisclosures. Overview 8/3/2016. SRS: Cranial and Spine
SRS: Cranial and Spine Brian Winey, Ph.D. Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Disclosures Travel and research funds from Elekta Travel funds from IBA
More informationOUTCOME OF CLIVAL CHORDOMAS AFTER SKULL BASE SURGERIES WITH MEAN FOLLOW - UP OF 10 YEARS
Fukushima J. Med. Sci., Vol. 61, No. 2, 2015 [Original Article] LONG - TERM OUTCOME OF CLIVAL CHORDOMAS J - STAGE Advance Publication, 1 September, 11, 2015 OUTCOME OF CLIVAL CHORDOMAS AFTER SKULL BASE
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017
More informationStereotactic Radiosurgery of World Health Organization Grade II and III Intracranial Meningiomas
Stereotactic Radiosurgery of World Health Organization Grade II and III Intracranial Meningiomas Treatment Results on the Basis of a 22-Year Experience Bruce E. Pollock, MD 1,2 ; Scott L. Stafford, MD
More informationDefining Target Volumes and Organs at Risk: a common language
Defining Target Volumes and Organs at Risk: a common language Eduardo Rosenblatt Section Head Applied Radiation Biology and Radiotherapy (ARBR) Section Division of Human Health IAEA Objective: To introduce
More informationStereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases
ONCOLOGY REPORTS 29: 407-412, 2013 Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases SHELLY LWU 1, PABLO GOETZ 1, ERIC MONSALVES 1, MANDANA ARYAEE 1, JULIUS
More informationOriginal Article. Teyyiba Kanwal, Muhammad Khalid, Syed Ijaz Hussain Shah, Khawar Nadeem
Original Article Treatment Planning Evaluation of Sliding Window and Multiple Static Segments Technique in Intensity Modulated Radiotherapy for Different Beam Directions Teyyiba Kanwal, Muhammad Khalid,
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO 06/24/2011 Section: Radiology Place(s) of
More informationNeutron Radiotherapy: Past, Present, and Future Directions
Neutron Radiotherapy: Past, Present, and Future Directions Theodore L. Phillips Lecture -- 2014 George E. Laramore Ph.D., M.D. NONE Conflicts of Interest Peter Wootton Professor of Radiation Oncology University
More informationChapter 5 Section 3.1
Radiology Chapter 5 Section 3.1 Issue Date: March 27, 1991 Authority: 32 CFR 199.4(b)(2), (b)(2)(x), (c)(2)(viii), and (g)(15) 1.0 CPT 1 PROCEDURE CODES 37243, 61793, 61795, 77261-77421, 77427-77799, 0073T
More informationDosimetry, see MAGIC; Polymer gel dosimetry. Fiducial tracking, see CyberKnife radiosurgery
Subject Index Acoustic neuroma, neurofibromatosis type 2 complications 103, 105 hearing outcomes 103, 105 outcome measures 101 patient selection 105 study design 101 tumor control 101 105 treatment options
More informationOverview of Advanced Techniques in Radiation Therapy
Overview of Advanced Techniques in Radiation Therapy Jacob (Jake) Van Dyk Manager, Physics & Engineering, LRCP Professor, UWO University of Western Ontario Acknowledgements Glenn Bauman Jerry Battista
More informationbrain SPINE 2 SRS Matures into breast lung spine LUNG Dr. Robert Timmerman Discusses SBRT for Inoperable Lung Cancer BRAIN
NEWS AND ADVANCES IN THE MANAGEMENT AND TREATMENT OF SERIOUS DISEASE brain SPINE 2 SRS Matures into Mainstream Extracranial Technique lung spine breast LUNG Dr. Robert Timmerman Discusses SBRT for Inoperable
More informationBLADDER RADIOTHERAPY PLANNING DOCUMENT
A 2X2 FACTORIAL RANDOMISED PHASE III STUDY COMPARING STANDARD VERSUS REDUCED VOLUME RADIOTHERAPY WITH AND WITHOUT SYNCHRONOUS CHEMOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER (ISRCTN 68324339) BLADDER RADIOTHERAPY
More informationImpact of Gamma Knife Radiosurgery on the neurosurgical management of skull-base lesions: The Combined Approach
Radiosurgery as part of the neurosurgical armamentarium: Educational Symposium November 24 th 2011 Impact of Gamma Knife Radiosurgery on the neurosurgical management of skull-base lesions: The Combined
More informationFEE RULES RADIATION ONCOLOGY FEE SCHEDULE CONTENTS
Tel: +27-21-9494060 Fax: +27-21-9494112 E-mail: leon.gouws@cancercare.co.za FEE RULES RADIATION ONCOLOGY FEE SCHEDULE CONTENTS 1. EXTERNAL BEAM RADIATION... 2 2. PLANNING OF TREATMENT... 2 3. DELIVERY
More informationCase Study. Institution Farrer Park Hospital
Case Study Single isocenter high definition dynamic radiosurgery (HDRS) for multiple brain metastases HDRS with Monaco, Versa HD and HexaPOD allows multiple brain metastases treatment within standard 15-minute
More information4D Radiotherapy in early ca Lung. Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla
4D Radiotherapy in early ca Lung Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla Presentation focus on ---- Limitation of Conventional RT Why Interest in early lung cancer
More informationA TREATMENT PLANNING STUDY COMPARING VMAT WITH 3D CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER USING PINNACLE PLANNING SYSTEM *
Romanian Reports in Physics, Vol. 66, No. 2, P. 394 400, 2014 A TREATMENT PLANNING STUDY COMPARING VMAT WITH 3D CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER USING PINNACLE PLANNING SYSTEM * D. ADAM 1,2,
More informationFractionated stereotactic radiation therapy improves cranial neuropathies in patients with skull base meningiomas: a retrospective cohort study.
Thomas Jefferson University Jefferson Digital Commons Department of Radiation Oncology Faculty Papers Department of Radiation Oncology 1-1-2012 Fractionated stereotactic radiation therapy improves cranial
More informationSBRT in early stage NSCLC
SBRT in early stage NSCLC Optimal technique and tumor dose Frank Zimmermann Clinic of Radiotherapy and Radiation Oncology University Hospital Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch Techniques
More informationStereotactic Radiosurgery/Fractionated Stereotactic Radiotherapy for Acoustic Neuroma (Vestibular Schwannomas)
Strategic Commissioning Group West Midlands Commissioning Policy (WM/38) Stereotactic Radiosurgery/Fractionated Stereotactic Radiotherapy for Acoustic Neuroma (Vestibular Schwannomas) Version 1 July 2010
More informationProton radiation therapy for chordomas and chondrosarcomas of the skull base
J Neurosurg 91:432 439, 1999 Proton radiation therapy for chordomas and chondrosarcomas of the skull base EUGEN B. HUG, M.D., LILIA N. LOREDO, M.D., JERRY D. SLATER, M.D., ALEXANDER DEVRIES, M.D., ROGER
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Proton Therapy
AMERICAN BRAIN TUMOR ASSOCIATION Proton Therapy ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit
More informationLet s speak the same language: Standardization in Terminology
Faculty Disclosure Let s speak the same language: Standardization in Terminology Michael Torrens Gamma Knife Department, Hygeia Hospital, Athens, Greece Why is standardization necessary? Neurosurgical
More informationRole of adaptive radiation therapy for pediatric patients with diffuse pontine glioma
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 12, NUMBER 2, spring 2011 Role of adaptive radiation therapy for pediatric patients with diffuse pontine glioma Chris Beltran, a Saumya Sharma, and Thomas
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationStereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13
Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall
More informationBrain Tumor Treatment
Scan for mobile link. Brain Tumor Treatment Brain Tumors Overview A brain tumor is a group of abnormal cells that grows in or around the brain. Tumors can directly destroy healthy brain cells. They can
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/20/2015
More informationAlessandra Gorgulho, MD, MSc
Manejo do Meningioma que compromete o seio cavernoso: quando eu irradio Alessandra Gorgulho, MD, MSc Chefe Clínico-Científica Centro HCor de Neurociências Professora Visitante, Departamento de Neurocirurgia,
More informationREVISITING ICRU VOLUME DEFINITIONS. Eduardo Rosenblatt Vienna, Austria
REVISITING ICRU VOLUME DEFINITIONS Eduardo Rosenblatt Vienna, Austria Objective: To introduce target volumes and organ at risk concepts as defined by ICRU. 3D-CRT is the standard There was a need for a
More informationCase Report Carbon Ion Beam Radiotherapy for Sinonasal Malignant Tumors Invading Skull Base
Case Reports in Otolaryngology, Article ID 241856, 4 pages http://dx.doi.org/10.1155/2014/241856 Case Report Carbon Ion Beam Radiotherapy for Sinonasal Malignant Tumors Invading Skull Base Nobuo Ohta,
More informationIMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia
IMRT - the physician s eye-view Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia The goals of cancer therapy Local control Survival Functional status Quality of life Causes
More informationPostoperative LINAC-Based Stereotactic Radiotherapy for Grade I Intracranial Meningioma in Subtype Classification
Postoperative LINAC-Based Stereotactic Radiotherapy for Grade I Intracranial Meningioma in Subtype Classification Peerapong Lueangapapong MD*, Mantana Dhanachai MD**, Ake Hansasuta MD* * Division of Neurosurgery,
More informationVariable Dose Rate Dynamic Conformal Arc Therapy (DCAT) for SABR Lung: From static fields to dynamic arcs using Monaco 5.10
Variable Dose Rate Dynamic Conformal Arc Therapy (DCAT) for SABR Lung: From static fields to dynamic arcs using Monaco 5.10 Simon Goodall Radiation Oncology Physicist Genesis Care Western Australia Introduction
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More information11/27/2017. Modern Treatment of Meningiomas. Disclosures. Modern is Better? No disclosures relevant to this presentation
Modern Treatment of Meningiomas Michael A. Vogelbaum MD, PhD Professor of Neurosurgery Cleveland Clinic Disclosures No disclosures relevant to this presentation IP and royalties related to drug and device
More informationFlattening Filter Free beam
Dose rate effect in external radiotherapy: biology and clinic Marta Scorsetti, M.D. Radiotherapy and Radiosurgery Dep., Istituto Clinico Humanitas, Milan, Italy Brescia October 8th/9th, 2015 Flattening
More information